spacer
home > white papers > High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts - ILC Dover
WHITE PAPERS
logo_ILC_DoverB.jpg

ILC Dover

phone +1 (302) 335-3911
web http://www.doverpac.com
email 1 Moonwalker Road, Frederica, DE 19946, United States

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Vaisala launches a completely new probe for the measurement of hydrogen peroxide


More info >>


White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>


Industry Events

BioProcess International Conference & Exhibition (BPI)

25-28 September 2017, Hynes Convention Center, Boston, Massachusetts, USA

BioProcess International Conference & Exhibition (BPI) is the largest bioprocessing event bringing you the science, technologies and partners needed to accelerate promising biologics towards commercial success.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement